Gattefossé unmasks oil-soluble bioactive for eye area care

Gattefossé has taken the wraps off Eyeglorius, a lipophilic active ingredient for eye area care.

The French manufacturer says Eyeglorius is capable of treating all signs of fatigue at the same time while opening up a myriad of possibilities for skincare and makeup formulations.

The active ingredient is derived from the leaves of sea buckthorn, which is reputed for its phytochemical richness, especially in triterpenic compounds.

Triterpenoid acids (mainly ursolic, maslinic, and oleanolic acids) have recognized effects on skin microcirculation by reducing inflammation-induced vascular permeability and reinforcing the endothelial barrier function.

The ingredient is 100% of natural origin according to the norm ISO16128, organic certified, RSPO mass balance certified and China NMPA notified.

A supply chain built with a Canadian family-owned orchard ensures the traceability and high organic quality of the raw material.

Two double-blind clinical studies have confirmed Eyeglorius efficiency in reducing signs of fatigue.

Tested against a placebo, it achieves a significant reduction of eye bags volume combined with a lighter appearance and smaller surface for dark circles.

Due to its lipophilic composition, Eyeglorius is said to a versatile technical ally for W/O and O/W formulations.

Moreover, being heat resistant, it can be incorporated into stick formulas or in a one-pot process.

“In response to the trend towards skinification in makeup, Gattefossé sought to provide cosmetic brands with a comprehensive solution,” said Gattefossé marketing leader for personal care actives Laurie Canel.

“We leveraged our multiple expertise to create Eyeglorius, a distinctive lipophilic active which is the perfect match between the expectations of formulators and consumers,” she added.

Latest Issues

9th Anti-Ageing Skin Care Conference

Royal College of Physicians, London
25th - 26th June 2024

in-cosmetics Korea 2024

Hall C, Coex, Seoul, South Korea
24th - 26th July 2024